BDBM323210 N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-methoxybenzyl)-2-oxoethyl]-3-(5-methyl-3H-[1,2,4]triazol-3-yl)propionamide::US9630949, 40

SMILES CCCCOC1(CN(C1)C(=O)[C@@H](Cc1ccc(OC)cc1)NC(=O)CCC1N=NC(C)=N1)c1ccccc1C

InChI Key InChIKey=PZERXNLKGYHOMB-UHFFFAOYSA-N

Data  2 EC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 2 hits for monomerid = 323210   

TargetMelanocortin receptor 4(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323210(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  500nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent

TargetMelanocyte-stimulating hormone receptor(Human)
Galderma Research & Development

US Patent
LigandPNGBDBM323210(N-[(R)-2-(3-butoxy-3-o-tolylazetidin-1-yl)-1-(4-me...)
Affinity DataEC50:  8.00E+3nMAssay Description:In the presence of an activator (agonist), the melanocortin receptor will activate the cAMP pathway which, via the CRE-Luc vector, will result in the...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/20/2019
Entry Details
US Patent